Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

34.04 +0.86 (+2.59%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about RAPT Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Rapt Therapeutics, Outperforming 98% Of All Stocks, Skyrockets After Topping Roche ↗
The company took on Roche's Xolair in a 16-week study of patients with a chronic hives disorder. 
Via Investor's Business Daily
News headline image
These stocks are moving in today's pre-market session ↗
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
RAPT on track to initiate trial this year 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Reports Second Quarter 2025 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position ↗
Clear Street’s initiated with a $3 price target, highlighting RPT904b as a “potentially best-in-class anti-IgE antibody.” 
Via Stocktwits
Topics ETFs
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
RAPT Therapeutics to Participate in Upcoming Investor Conferences
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
RAPT Therapeutics Reports First Quarter 2025 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics to Participate in Upcoming Investor Conferences
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
From RAPT Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.